Randomized Evaluation and Verification of Ventricular Enhancement (REVIVE-HF)
Randomized Evaluation and Verification of Ventricular Enhancement: The REVIVE-HF Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Berlin, Germany, 13353
- German Heart Institute Berlin and Charité University Medicine Berlin
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients suffering from heart failure symptoms with cardiac dysfunction caused by a previous myocardial infarction resulting in increased LV systolic volume and in a discrete, contiguous, acontractile, (akinetic and/or dyskinetic) scar located in the antero-septal, apical (may extend laterally) region of the left ventricle.
Exclusion Criteria:
- Calcified ventricular wall in the area of intended scar exclusion as verified by one or more appropriate imaging modalities;
- Inadequate myocardial viability in regions remote from the scar.
- Thrombus or intra-ventricular mass in the left atrium or ventricle as verified by echocardiography or equivalent that has not been adequately treated with weeks of anticoagulant at therapeutic levels;
- Cardiac Resynchronization Therapy (CRT) consisting of Bi-ventricular pacemaker device (i.e., not ICD only) placement ≤ 60 days prior to treatment;
- Patient intolerance or unwillingness to take anti-coagulation medication;
- Functioning pacemaker leads in antero-apical RV, which, in the opinion of the investigator, would interfere with anchor placement;
- Pulmonary Arterial Pressure > 60 mm Hg shown by right heart catheterization to be precapillary or unresponsive to vasodilator therapy;
- Myocardial Infarction within 90 days prior to the procedure;
- Previous right neck surgery, previous pericardiotomy, previous left chest surgery that precludes device placement;
- Chronic renal failure with a serum creatinine >2 mg/dL;
- Inoperable coronary disease with significant ischemia or pulmonary disease that would preclude transient single lung ventilation.
- Baseline 6-minute walk distance of >450m
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Revivent TC Ventricular Enhancement System plus GDMT
Patients will receive treatment with the Revivent TC Ventricular Enhancement System while being maintained on Guideline Directed Medical Therapy for treatment of Heart Failure.
|
Anchors that are implanted into the left ventricle to reshape and reduce the size and increase the efficiency of the pumping chamber.
Guideline Directed Medical Therapy
|
|
Active Comparator: GDMT Only
Patients will be maintained on Guideline Directed Medical Therapy for treatment of Heart Failure.
|
Guideline Directed Medical Therapy
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
6 Minute Walking Distance
Time Frame: 3 and 6 months after enrollment
|
Improvement of heart failure symptoms compared to baseline as measured by changes in 6 Minute Walking Distance.
|
3 and 6 months after enrollment
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Quality of Life Index
Time Frame: 3 and 6 months after enrollment
|
Changes in Quality of Life Index measured compared to baseline using the MLHFQ Quality of Life Questionnaire.
|
3 and 6 months after enrollment
|
|
NYHA Classification
Time Frame: 3 and 6 months after enrollment
|
Changes in NYHA Heart Classification compared to baseline
|
3 and 6 months after enrollment
|
|
LVESVI and LVEDVI
Time Frame: 3 and 6 months after enrollment
|
Changes in left ventricular end systolic volume index (LVESVI) end diastolic volume index (LVEDVI) measured by echocardiogram compared to baseline
|
3 and 6 months after enrollment
|
|
LVEF
Time Frame: 3 and 6 months after enrollment
|
Changes in left ventricular ejection fraction (LVEF) measured by echocardiogram compared to baseline
|
3 and 6 months after enrollment
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Stefan Anker, MD, Berlin-Brandenburger Centrum für Regenerative Therapien (BCRT) und Medizinische Klinik m. S. Kardiologie
- Principal Investigator: Volkmar Falk, MD, Ärztlicher Direktor, Direktor der Klinik für Herz-Thorax-Gefässchirurgie, Deutsches Herzzentrum Berlin
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CIP-0080
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.